Jacob P. Laubach - Dana-Farber Cancer Institute, Boston, MA 02115, USA

基本信息

浏览量：252

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 381 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

Elizabeth O'Donnell,Clifton Mo,Andrew J Yee,Omar Nadeem,Jacob Laubach,Jacalyn Rosenblatt,Nikhil Munshi,Shonali Midha,Diana Cirstea, Pavlina Chrysafi,Nora Horick,Paul G Richardson,

The Lancet Haematology (2024)

引用0浏览0引用

Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma

Monique A. Hartley-Brown,Clifton C. Mo,Omar Nadeem,Shonali Midha,Jacob P. Laubach,Paul G. Richardson

Cancersno. 6 (2024)

引用0浏览0引用

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

Elizabeth O'Donnell,Clifton Mo,Andrew J Yee,Omar Nadeem,Jacob Laubach,Jacalyn Rosenblatt,Nikhil Munshi,Shonali Midha,Diana Cirstea, Pavlina Chrysafi,Nora Horick,Paul G Richardson,

The Lancet Haematology (2024)

引用0浏览0引用

Rebecca Silbermann,Jacob Laubach,Jonathan L Kaufman,Douglas W Sborov,Brandi Reeves,Cesar Rodriguez,Ajai Chari,Luciano J Costa, Larry D Anderson,Nitya Nathwani,Nina Shah,Naresh Bumma,

American journal of hematology (2024)

引用0浏览0WOS引用

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Paul G. Richardson, Brian G. Durie,Laura Rosinol,Maria-Victoria Mateos,Angela Dispenzieri,Philippe Moreau,Shaji Kumar,Noopur Raje,Nikhil Munshi,Jacob P. Laubach, Peter O'Gorman, Elizabeth O'Donnell,

HAEMATOLOGICAno. 11 (2023): 2894-2912

引用0浏览0引用

Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma

Jonathan Kaufman,Hang Quach,Rachid Baz,Annette Juul Vangsted,Shir-Jing Ho,Niels Abildgaard,Jacob Laubach,Vincent Ribrag,Simon Gibbs,Eva Medvedova,Peter Voorhees,Muhammad Jalaluddin,

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S188-S189

引用0浏览0引用

Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Sophie Magidson,Robert A. Redd,Jacob Laubach,Clifton C. Mo,Elizabeth K. O'Donnell,Adam S. Sperling, Monique A. Hartley-Brown, Shonali Midha, Marjorie Marto, Christine Davie, Caroline Ricciardi,

BLOODno. Supplement 1 (2023): 3382-3382

引用0浏览0引用

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Omar Nadeem, Sophie Magidson,Shonali Midha, Elizabeth K. O'Donnell,Monique A Hartley-Brown,Adam S. Sperling,Robert A. Redd, Marjorie Marto,Christine Davie, Caroline Ricciardi,Dechen Choden, Ashlee Strutevant,

Blood (2023): 206

引用0浏览0引用

Expansion, persistence, and characteristics of autologous, BHV-1100 ARMored memory-like NK cells infused prior to autologous stem cell transplant in MRD plus , newly diagnosed multiple myeloma patients

Grace Birch, Juliana Vergara-Cadavid,Michela Ansuinelli,Tuyet Nguyen,Carol Reynolds, Soo Im, Hope Wei,Sarah Hogan, Elizabeth Kendricken,Adam Sperling,Omar Nadeem,Shonali Midha,

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S34-S35

引用0浏览0引用

Real world experience of patients treated with teclistamab: a BCMA-directed bispecific T-cell engaging therapy for multiple myeloma

Shonali Midha,Houry Leblebjian,Jacob Laubach,Clifton Mo,Adam Sperling,Omar Nadeem,Giada Bianchi,Monique Hartley-Brown, Linda Ramsdell,Kristen Donadio, Emerald Chun, Megan Belanger,

Clinical Lymphoma, Myeloma & Leukemia（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn